Li Xiaoyi, Zhu Lixin, Wang Beibei, Yuan Meifei, Zhu Ruixin
Department of Gastroenterology, School of Life Sciences and Technology, Shanghai East Hospital, Tongji University, Shanghai, China.
Department of Pediatrics, Digestive Diseases and Nutrition Center, State University of New York at Buffalo, Buffalo, NY, United States.
Front Pharmacol. 2017 Nov 23;8:855. doi: 10.3389/fphar.2017.00855. eCollection 2017.
Fibrosis contributes to the development of many diseases and many target molecules are involved in fibrosis. Currently, the majority of fibrosis treatment strategies are limited to specific diseases or organs. However, accumulating evidence demonstrates great similarities among fibroproliferative diseases, and more and more drugs are proved to be effective anti-fibrotic therapies across different diseases and organs. Here we comprehensively review the current knowledge on the pathological mechanisms of fibrosis, and divide factors mediating fibrosis progression into extracellular and intracellular groups. Furthermore, we systematically summarize both single and multiple component drugs that target fibrosis. Future directions of fibrosis drug discovery are also proposed.
纤维化促成了许多疾病的发展,且许多靶分子参与其中。目前,大多数纤维化治疗策略局限于特定疾病或器官。然而,越来越多的证据表明纤维增生性疾病之间存在很大相似性,并且越来越多的药物被证明是跨不同疾病和器官的有效抗纤维化疗法。在此,我们全面综述了目前关于纤维化病理机制的知识,并将介导纤维化进展的因素分为细胞外和细胞内两组。此外,我们系统总结了靶向纤维化的单组分和多组分药物。还提出了纤维化药物研发的未来方向。